NCP Inc’s GSK GSK Stock Holding History

NCP Inc’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8K	Hold	320	–	–	0.02%	68
2026 Q1	$17.7K	Hold	320	–	–	0.03%	61
2025 Q4	$15.7K	Buy	+320	New	+$14.9K	0.01%	113

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NCP Inc's GSK Position: Q2 2026 in Review

NCP Inc held its GSK (GSK) position steady in Q2 2026 at 320 shares worth $16.8K. The position accounts for 0.02% of the portfolio, ranked #68.

NCP Inc first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.7K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

NCP Inc held 320 shares of GSK worth $16.8K as of Q2 2026.
NCP Inc left its GSK share count unchanged in Q2 2026.
GSK made up 0.02% of NCP Inc's portfolio in Q2 2026, its #68 holding.
NCP Inc first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
NCP Inc's GSK position peaked at $17.7K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on NCP Inc's 13F filing for Q2 2026, filed 13 Aug 2026.